MDGL
Madrigal Pharmaceuticals Delivers Strong Q2 Results, Solidifying Leadership in MASH Market
Madrigal Pharmaceuticals, a leading biopharmaceutical company, has reported impressive second-quarter results for 2026. During the earnings conference call on July 30th, executives highlighted the company's continued growth and leadership in the Market Abuse Syndrome (MASH) market. Bill Sibold, Chief Executive Officer of Madrigal Pharmaceuticals, emphasized that the company